NCT06033703View on ClinicalTrials.gov

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients with Retinal Detachment

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Rhegmatogenous Retinal DetachmentProliferative Vitreoretinopathy
Interventions
DRUG

Netarsudil Ophthalmic

Topical administration of Netarsudil

All Listed Sponsors
lead

Massachusetts Eye and Ear Infirmary

OTHER

NCT06033703 - Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients with Retinal Detachment | Biotech Hunter | Biotech Hunter